PPLPHARMAPiramal Pharma Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
₹178.87
▼ 0.31%Decent
Price & Volume
Loading chart…
Key Ratios
Market Cap (₹ cr)23,733.30
P/E—
P/B2.91
PEG—
ROE %-4.00
ROCE %1.10
Debt / Equity0.70
EPS-2.46
Revenue Growth %-0.10
Profit Growth %-457.70
Dividend Yield %0.00
Promoter Holding %54.45
FII Holding %21.32
DII Holding %—
Beta0.39
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
| Pullback to 21-EMA | LONG | 64% | ₹178.87 | ₹170.61 | ₹188.98 | 1.22 |
| Golden Cross | LONG | 55% | ₹178.87 | ₹166.11 | ₹204.39 | 2.00 |
HOLDConviction 56%
The picture
- • Debt/Equity: 0.70
- • Promoter holding: 54.5%
- • RSI: 60
- • MACD: bullish
- • Price vs EMA21: above
- • 1-month return: +12.6%
- • Golden Cross signal (setup quality 55%)
- • Pullback to 21-EMA signal (setup quality 64%)
Bull case
- • Debt/Equity: 0.70
- • Promoter holding: 54.5%
- • RSI: 60
- • MACD: bullish
Bear case
- • Revenue growth: -0.1% YoY
- • Profit growth: -457.7% YoY
- • Volume: 0.4x 20-day average
- • Volume trend: 0.7x baseline
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -0.1% YoY
- • Profit growth: -457.7% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Entry (CMP)
₹178.87
Stop Loss
₹162.57
risk 9.1%
Target 1 (1.5R)
₹203.32
+13.7%
Target 2 (3R)
₹227.77
+27.3%
Support (20d)
₹158.99
Resistance (52w)
₹220.85
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹16.30/share
ATR (volatility)
₹6.52
avg daily range
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹6.52). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.
Score Breakdown
Fundamental
21
Technical
72
Momentum
77
Risk (safety)
59